Lineage Cell Therapeutics
LCTX
#8657
Rank
$0.11 B
Marketcap
$0.60
Share price
-6.45%
Change (1 day)
-43.93%
Change (1 year)

Operating Margin for Lineage Cell Therapeutics (LCTX)

Operating Margin as of November 2024 (TTM): -260.27%

According to Lineage Cell Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -260.27%. At the end of 2023 the company had an Operating Margin of -260.28%.

Operating Margin history for Lineage Cell Therapeutics from 2001 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
2023-260.28%48.26%
2022-175.56%-84.19%
2021-1,110.63%-60.84%
2020-2,836.22%117.94%
2019-1,301.35%-60.9%
2018-3,328.39%156.11%
2017-1,299.61%-257.17%
2016826.87%-133.44%
2015-2,472.38%-5.9%
2014-2,627.38%33.77%
2013-1,964.03%31.39%
2012-1,494.85%35.11%
2011-1,106.43%24.53%
2010-888.48%385.89%
2009-182.86%-2.58%
2008-187.70%60.64%
2007-116.85%-22.49%
2006-150.76%-32.54%
2005-223.47%-21.86%
2004-286.00%-5.83%
2003-303.70%-42.23%
2002-525.72%-77.15%
2001-2,300.33%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
0.00%N/A๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.